Your session is about to expire
← Back to Search
Acalabrutinib for Diffuse Large B-Cell Lymphoma
Study Summary
This trial looked at the safety of a new drug, acalabrutinib, in people with a certain type of lymphoma that has come back or does not respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 177 Patients • NCT04346199Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have any severe illnesses that could affect my safety or the study's results.I have a condition that affects how my stomach or intestines absorb food.I am 18 years old or older.My condition has returned or didn't respond to treatment.I do not have serious heart problems like recent heart attacks or severe heart failure.My cancer is a type of aggressive lymphoma diagnosed for the first time.I have at least one tumor that can be measured.
- Group 1: Acalabrutinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this the inaugural trial of its type?
"Since 2014, Acalabrutinib has been thoroughly studied. Its first clinical trial (sponsored by Acerta Pharma BV) took place in the same year and involved 306 patients. The drug received its Phase 1 & 2 approval afterwards and is currently being evaluated at 75 active studies around 507 cities across 47 nations."
Have any prior experiments been conducted with Acalabrutinib?
"At present, there are 75 active studies concerning Acalabrutinib with 11 trials in their final phase. Most of the clinical investigations related to this drug take place within Houston, TX; however, it is also being studied across 2427 other sites."
What is the safety profile of Acalabrutinib for those in treatment?
"Acalabrutinib's safety was assigned a value of 1 due to the early phase nature of this trial, which indicates limited evidence for both efficacy and security."
Is this clinical trial recruiting participants of all ages, or is there an upper age limit?
"The parameters of the inclusion criteria dictate that prospective participants must be at least 18 years old and not older than 130."
Is this research project currently enrolling participants?
"At present, this research is not recruiting any further participants. The trial was published on August 7th 2014 and the latest update occurred on September 1st 2022. On the other hand, 1766 studies are actively seeking patients with lymphoma while 75 trials offer Acalabrutinib treatment to enrolled individuals."
What is the cap on enrollees for this medical experiment?
"Though the trial was initially posted in 2014 and updated as recently as September 1st 2022, it is not currently seeking patients. There are however 1766 trials recruiting for lymphoma research and 75 clinical studies that employ Acalabrutinib actively looking to enrol volunteers."
How many venues are executing this experiment?
"This clinical trial is presently recruiting from 5 distinct medical centres, including Los Angeles, Columbus and Atlanta. It may be beneficial to choose the closest site for enrolment in order to reduce travel needs."
Is it possible to register for participation in this experiment?
"For this trial, 21 volunteers that are between 18 and 130 years old with lymphoma must be enlisted. Furthermore, they need to meet the following criteria: Gender requirements (male or female), Pathological verification of their DLBCL diagnosis, Evidence of relapse/resistance to earlier treatment regimens and At least one measurable site for disease evaluation."
What medical conditions have been treated most successfully with Acalabrutinib?
"Acalabrutinib is an effective therapy for treating mantle cell lymphoma (MCL), small lymphocytic lymphoma, and chronic lymphocytic leukemia (CLL)."
Share this study with friends
Copy Link
Messenger